Avalyn Pharma Inc. (AVLN) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-05

Key Insights

FMR LLC (Fidelity) converted 2.28 million shares of preferred stock into common stock on May 1, 2026, in connection with Avalyn Pharma's IPO, indicating a major institutional investor transition from private to public ownership.
FMR LLC holds a significant 10% beneficial ownership stake in AVLN through indirect ownership via F-Prime Capital Partners Healthcare Fund V LP, establishing it as a major shareholder in the newly public company.
The conversion involved five different preferred stock series (A, B, C-1, C-2, and D) all converting on a 1-for-1 basis, reflecting a standard IPO capitalization restructuring with no apparent dilution or preferential treatment.
As a Director and 10% owner, FMR LLC has both governance influence and substantial financial stake in Avalyn Pharma's success, though the filing disclaims admission of beneficial ownership per standard SEC language.

Want the newest filings?

This analysis covers the filing from 2026-05-05. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-05-05

Novo Holdings A/S, a 10% owner and director of Avalyn Pharma, acquired 555,555 common shares at $18 per share on 05/01/2026, demonstrating continued investment commitment during or around the company's IPO period.
The filing documents the automatic conversion of 63.0 million preferred shares (Series A through D) into approximately 3.3 million common shares on a 1-for-19.2417 basis upon IPO closing, reflecting standard IPO conversion mechanics and establishing Novo Holdings' substantial post-IPO ownership position.
Novo Holdings' total beneficial ownership reached 3.88 million voting common shares following these transactions, indicating a significant strategic stake in the newly public company with continued confidence in its valuation and prospects.

Other reports for Avalyn Pharma Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.